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Introduction 
The emergence of virally mediated head and neck cancers (VMHNC) has 
presented the oncology community, and in particular radiation oncology, with 
some unique challenges.  These patients generally present younger, in better 
health compared with historical head and neck cancer patients, have 
radioresponsive disease and good prognosis, meaning that the development of 
strategies to minimise their long-term side effects is vital.1  
 
Head and neck cancer patients often experience numerous anatomical changes 
during treatment.2  These can be externally visible, including tumour and nodal 
regression and weight loss, and internal, including parotid gland volume 
changes.3,4  These changes may result in differences in dose distribution, 
causing potential underdosing of target volumes and/or overdosing of 
surrounding normal and critical tissue.5  This is of particular importance when 
highly conformal techniques, such as intensity modulated radiotherapy (IMRT) 
techniques are used because of the steep dose gradients that can be created 
between target volumes and surrounding normal and critical tissues.6  Adaptive 
radiotherapy is one dosimetric approach that can be employed to account for 
ongoing treatment-induced changes in anatomy and so minimise the impact on 
highly conformal IMRT dose distributions.7 
 
This study was a retrospective review of patients with VMHNC, who attended the 
Princess Alexandra Hospital (PAH) for definitive radiotherapy between 2005 and 
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2010.  Patients who underwent a re-plan, due to anatomical changes identified 
by radiation therapists during their radiotherapy treatment course, were 
investigated.  Both virally mediated nasopharyngeal cancer (NPC) and 
oropharyngeal cancer (OSCC) were studied as collectively, these VMHNC's 
represent a subset of cancers that are clinically distinct.8  They have a greater 
likelihood of response to therapy, are not necessarily related to smoking, have a 
more favourable prognosis and a different pathway of malignant transformation.8  
The primary aim of this investigation was to evaluate the effect of treatment-
induced anatomical changes, such as weight loss and tumour or nodal shrinkage, 
on the planned dose distribution to assist in the development of appropriate 
adaptive radiotherapy strategies. 
 
Methods and Materials 
Patients 
Patients with VMHNC who received definitive radiotherapy treatment with or 
without systemic therapy, between 2005 and 2010 were identified from a 
prospective head and neck database at PAH.  Eligibility criteria included: 
histologically confirmed NPC or OSCC, with either positive serology for Epstein 
Barr Virus (EBV) or Human Papillomavirus (HPV) (p16 immunostaining >70%), 
respectively, and node positive disease with any T stage disease and treatment 
plan accessible on the treatment planning system.  Patients who had a re-plan 
generated during their treatment were selected in order to examine the 
volumetric and dosimetric changes between the planning scan and the repeat 
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planning CT scan (re-CT).  At the time of the study, there was no protocol to 
identify patients requiring re-planning and decisions were made based on the 
treating radiation therapists’ judgement on a daily basis.  These decisions were 
informed by the evaluation of the mask fit and assessment of weekly separation 
measurements.  If a change in separation reading of greater than 1cm occurred, 
the plan was returned to planning for review and potential re-CT.  Patient 
demographics and tumour characteristics, including pre-treatment size of the 
dominant node, were recorded.  Nodal size data was collected from each 
patient’s diagnosis and staging information.  Patient weight was measured by a 
radiation oncology nurse or dietician at the time of planning and at re-CT. The 
project was approved by the Human Research Ethics Committees from the PAH 
and Queensland University of Technology. 
 
Re-CT and volumetric change evaluation 
Each patient’s re-CT was performed in the same position as the planning CT.  
The re-CT was manually fused with the planning CT using the registration match 
point/region prescribed by the radiation oncologist and this registration was 
checked by both a senior radiation therapist and the radiation oncologist.  The 
primary and nodal gross target volumes and specific organs at risk (OAR) were 
re-contoured by a radiation oncologist on the re-CT to determine if any volumetric 
changes had occurred.  The same radiation oncologist did not contour these 
volumes on both the planning CT and re-CT in all cases.  The volumes were 
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recorded for the primary and nodal gross target volumes and left and right parotid 
glands.   
 
Dosimetric effect evaluation 
The effect of any treatment-induced anatomical changes on the dose distribution 
was quantified by comparing the primary plan with a comparison plan.  All plans 
were calculated on the Eclipse treatment planning system (version 8.6, Varian 
Medical Systems, Palo Alto, CA, USA).  The primary plan was calculated using 
the original CT data.  The comparison plan used the same treatment fields from 
the primary plan but calculated on the re-CT data.  The monitor units (MU) for all 
treatment fields remained the same for both plans to ensure that the dosimetric 
effect of anatomical changes could be accurately recorded.  For three-
dimensional conformal (3DCRT) plans, the comparison plan was created by one 
radiation therapist who replicated the primary plan, at the same isocentre position, 
using the re-CT data.  The plan was then calculated and doses adjusted to 
represent the treatment portions delivered before and after the observation of 
anatomical changes.  For IMRT plans the fluence map from the primary plan was 
used to calculate the comparison plan.  The dosimetric effect was quantified by 
comparing dose volume histograms (DVH) of primary and nodal gross target 
volumes (GTV-p and GTV-n) and OAR from both plans.  OAR investigated were 
spinal cord, brainstem and left and right parotid glands.  
 
Statistics 
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Data were analysed using the Stata (version 12.1, StataCorp LP, Texas, USA) 
program. Doses to target volumes and OAR were recorded from both the initial 
and comparison plans.  The re-CT data was also examined to assess volumetric 
changes in tumour, nodal and parotid volumes and weight loss.  Statistical 
analysis included basic descriptive statistics to determine the impact of 
treatment-induced anatomical changes on the dose distribution.  Mann-Whitney-
Wilcoxon tests were used to analyse the comparison of changes in volume and 
dose of target volumes and OAR for the initial plan and the comparison plan.  A 
p-value of 0.05 was considered statistically significant.  
 
Results 
Patient characteristics 
Sixteen patients had a re-plan calculated and were selected for the study.  Three 
patients were excluded from this investigation.  Of these, one was unable to be 
retrieved from archive, one primary treatment plan was not utilised as the patient 
returned at a later date to receive treatment and one was only planned to receive 
a dose of 50 Gy.  The demographics of these patients are shown in Table 1.  
Eleven patients were male and 2 were female, 10 patients had HPV-positive 
OSCC and 3 had EBV-positive NPC.  Five (50%) of oropharynx patients were 
staged as having T2-3N2 disease and 2 (66.7%) nasopharynx patients, T4N2 
disease.   Eleven patients in this study were treated with 3DCRT and 2 patients 
were treated with IMRT.  All patients were prescribed and treated to a total dose 
of 70 Gy in 35 fractions.  The details of the prescription and OAR tolerances used 
 6 
are outlined in Table 2.  At least one parotid gland was spared where possible, 
ideally to a mean of < 26 Gy, but up to a mean of 33 Gy, as the specified 
tolerance dose.9  Re-plans were generated at a mean time point of fraction 22 
(range 17-29).    Eight (61.5%) patients underwent a re-CT and re-plan due to a 
combination of 2 factors: weight loss and tumour and/or nodal regression.  The 
reason for re-CT and re-plan for the remaining 5 patients were weight loss or 
tumour regression alone and a pre-scheduled re-plan of the lower neck area.  
Only 3 of the 13 (23.1%) patients actually had the plan from the re-CT clinically 
implemented.  This was due to the fact that the DVHs of target and OAR were 
considered clinically unacceptable by the treating radiation oncologist. 
 
Weight loss and volume reduction 
The weight loss and volume changes for GTVs and the parotid glands are 
demonstrated in Figure 1 and Table 3.  All patients experienced weight loss 
during treatment.  The overall mean percentage weight loss was 6.5%.  
Reduction in volume was observed for both target volumes and all OAR studied 
however, only the GTV-p and GTV-n approached statistical significance (p=0.06 
and p=0.09).  The greatest mean volume reduction seen was for the GTV-n with 
a 50.8% reduction being recorded.  One patient was excluded from the GTV-p 
results due to incomplete volumes.  The greatest percentage mean volume 
change for OAR was recorded for the parotid glands with a volume reduction of 
21.8% and 26.4% for the left and right glands respectively. 
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Dosimetric effect 
The details of the dose comparison between the primary plan and the 
comparison plan are demonstrated in Table 4.  The mean dose encompassing 
98% of the GTV-p and GTV-n volumes (D98) was slightly decreased when 
comparing the primary plan with the comparison plan.  In contrast, the mean 
doses to all OAR investigated increased with the greatest increase being for the 
maximum spinal cord dose (4.1%).  Eleven (84.6%) patients had an increase in 
dose to 2 or more OAR when comparing the primary plan with the comparison 
plan.  While none of the differences were statistically significant (p>0.05), greater 
dose variations and larger standard deviations were observed for the OAR in 
comparison to the target volumes.  The GTV-p had a range of 61.7 Gy to 70.1 Gy 
and the GTV-n had a range of 58.9 Gy to 71.1Gy.  The left parotid had a range of 
35.1 Gy and 69.3 Gy and and the right parotid had a range of 31.3 Gy and 68.6 
Gy.  This is consistent with the primary planning objective of covering the target 
volumes with the prescribed dose.   
 
The observed range of treatment-induced anatomical changes experienced 
resulted in a larger dosimetric effect in some patients.  In one patient, anatomical 
changes resulted in only a minimal change in target volume D98 dose (-0.2% 
and 2.2% in GTV-p and GTV-n respectively) but a much greater impact on OAR 
doses; 4.2% increase in maximum spinal cord dose and 13.4% and 8% increase 
in left and right parotid gland mean doses respectively. 
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Discussion 
This study showed that treatment-induced anatomical changes had the greatest 
impact on the OAR, increasing the doses received with negligible dose decrease 
to the primary and nodal GTVs.  These results, while not statistically significant, 
are of clinical importance as the observed dosimetric impact could result in the 
tolerance dose of an OAR being exceeded.  As an example, one patient studied 
was originally planned to receive a maximum spinal cord dose of 46.2 Gy but due 
to treatment-induced anatomical changes, received 54.1 Gy.  This overdosing of 
OAR can result in increased acute and long-term toxicity experienced by the 
patient and a reduction in their overall quality of life.  Consequently, it is 
imperative that the effect of these anatomical changes is considered and 
accounted for.  This is of particular importance with the parotid glands as, due to 
their steep dose-response relationship, exceeding the tolerance dose could result 
in permanent loss of salivary function.10   
 
Previous studies have also demonstrated the decrease in volume and 
subsequent increase in dose received by the parotid glands.7,11-14  Beltran and 
colleagues15 have reported an increase of 2.5 % in spinal cord dose and an 
increase of 4.7 % and 6.7 % in mean parotid gland dose during head and neck 
IMRT.  In contrast to the present study, they also reported a significant decrease 
in dose (D98) to the primary target volumes (p value=0.01).15  This difference 
could be due in part to the fact that only GTV dose coverage was measured in 
the present study whereas the study by Beltran primarily reported the planning 
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target volume (PTV) dose.  When specifically focusing on the GTV D98 dose, 
only a slight effect is observed: a 0.2% decrease in the present study and a 0.4% 
increase in the Beltran study.  In addition, only patients receiving IMRT were 
reported by Beltran and colleagues whereas the majority of patients in the 
present study were treated with 3DCRT.  It is well recognised that the steep dose 
gradients created with IMRT can make it more sensitive to treatment-induced 
anatomical changes, resulting in potential underdosing and/or overdosing of 
target and OAR volumes.5,12,15  The dosimetric effect observed in patients who 
received 3DCRT, may be magnified under IMRT, particularly for OAR such as 
the parotid glands which are known to shift medially into higher dose areas with 
weight loss and tumour regression.3  The added workload associated with the re-
planning process can place substantial burden on busy radiotherapy 
departments and further highlights the importance of appropriate, evidence-
based adaptive radiotherapy protocols for head and neck IMRT.16  The wide 
range of parotid gland doses observed in the study may be related to a number 
of factors: initial parotid size, differences in disease pathology, differential 
shrinkage of the surrounding nodes and the improvement in radiotherapy 
treatment techniques used over the study period. 
 
The adaptive radiotherapy protocols developed as part of this study will be tested 
in conjunction with daily image guidance using volumetric imaging allowing the 
exact timing of treatment-induced anatomical changes to be determined.  This 
will enable accurate evaluation of their dosimetric impact and will maximise the 
 10 
benefit of adaptive intervention.    Comprehensive assessment of the dosimetric 
impact of anatomical changes was not possible in the present study as daily 
volumetric imaging was not used.  As a result, the exact time point at which they 
occurred could not be determined.  The re-CTs used for dosimetric evaluation 
were performed after treatment staff had observed the anatomical changes. 
 
The inherent risk in retrospective studies, particularly the lack of control over data 
consistency, in combination with the small sample size means that cautious 
interpretation of the results should be undertaken.  It is likely the small sample 
size meant the study was insufficiently powered to detect any significant 
differences.  Another limitation of the study was that the variability in contouring 
of target and OAR volumes between the planning CT and re-CT was not 
accounted for and may have impacted the volumetric and dosimetric results.  
Nonetheless, the results of this study support the dosimetric impact of treatment-
induced changes and provide baseline data for the development of appropriately 
focused adaptive treatment strategies.  The clinically important dosimetric effect 
on OAR demonstrated in this study warrants further investigation with a larger 
sample size. 
 
Conclusion 
In this study, treatment-induced anatomical changes had the greatest impact on 
OAR dose.  The dosimetric impact observed is of clinical consequence and could 
potentially lead to exceeding an OAR tolerance dose.  The development of 
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adaptive radiotherapy strategies targeted at reducing OAR dose, while 
maintaining target volume dose, will be of great importance to patient long-term 
quality of life and departmental efficiency.  In the era of IMRT, accounting for 
treatment-induced anatomical changes is paramount due to the steep dose 
gradients between target volumes and OAR.  This is of particular relevance to 
patients with VMHNC as their increased responsiveness to radiotherapy often 
leads to a favourable prognosis. Although this study investigated only VMHNC, 
the adaptive radiotherapy strategies developed using these findings and 
associated dosimetric impact will be evaluated in a larger prospective study 
including all head and neck cancer patients with stratification between VMHNC 
and non-VMHNC patients.  
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Figure legend 
Figure 1 (a–d) Volume changes of (a) primary gross target volume (GTV-p), 
(b) nodal gross target volume (GTV-n), (c) left parotid gland and (d) 
right parotid gland between the planning CT and Re-CT. The box 
represents standard deviation (SD), and the horizontal line in the 
box represents the mean of the volumes. The bar represents the 
range of the volumes.  The dots represent outlying measurements. 
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Table 1 Patient characteristics 
 
  Characteristics 
Sex  
Male 11 
Female 2 
Age mean (range) 50 (36-64) 
Primary tumour site  
Tonsil 6 
Base of tongue 4 
Nasopharynx 3 
T classification  
1 1 
2 5 
3 3 
4 4 
N classification  
1 1 
2 8 
3 4 
Smoking history  
Never 4 
Former 3 
Active 6 
Nodal size mean (range) 48.8mm (24mm-90mm) 
Treatment technique  
3DCRT 11 
IMRT 2 
Mean timing of re-CT #22 (#17-#29) 
Re-plan implemented 3 
 
3DCRT - three-dimensional conformal radiation therapy 
IMRT - intensity modulated radiation therapy 
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Table 2 Prescription and OAR dose tolerances 
 
Structure Dose 
Prescription 70Gy in 35# 
Spinal cord ≤ 45Gy 
Brainstem ≤ 54Gy 
Parotid glands Mean dose ≤ 33Gy 
 
OAR - organ at risk
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Table 3 Mean weight and volume reduction details 
 
Structure Planning CT 
(range) 
Re-CT 
(range) 
Difference p-value 
Mean weight 
(kg) 
81.7  
(51.8 - 127.5) 
76.4 
(42.9 - 116.6) 
5.3  
(6.5%) 
0.40 
Mean GTV-p* 
volume (cc) 
32.3 
(14.9 - 52.3) 
22.6 
(0.4 - 49.1) 
9.7 
(30%) 
0.06 
Mean GTV-n 
volume (cc) 
56.1 
(6.4 - 240.2) 
27.6 
(3.8 - 116.6) 
28.5 
(50.8%) 
0.09 
Mean Lt 
Parotid volume 
(cc) 
24.8 
(9.1 - 53.4) 
19.4 
(7.9 - 38.6) 
5.4 
(21.8%) 
0.27 
Mean Rt 
Parotid volume 
(cc) 
25.0 
(9.5 - 48.8) 
18.4 
(7.8 - 31.6) 
6.6 
(26.4%) 
0.15 
* One patient excluded due to incomplete voluming 
GTV-p - primary gross target volume 
GTV-n - nodal gross target volume 
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Table 4 Mean doses to tumour and OAR volumes 
 
Structure Primary plan  
± SD (Gy)  
Comparison 
plan ± SD (Gy) 
Difference 
(Gy) 
p-value 
Mean GTV-p 
D98* 
 
66.9 ± 2.6 
 
66.8 ± 2.7 
 
-0.1  
(-0.15%) 
0.95 
Mean GTV-n 
D98 
 
67.6 ± 2.8 
 
67.4 ± 3.9 
 
-0.2 
(-0.3%) 
0.83 
Mean Plan 
max 
 
77.2 ± 1.8 
 
76.9 ± 1.9 
 
-0.3 
(-0.39%) 
1.00 
Mean Spinal 
cord max 
43.6 ± 3.8 
 
45.4 ± 4.8 
 
1.8 
(4.1%) 
0.47 
Mean 
Brainstem max 
42.1 ± 14.0 
 
43.2 ± 11.8 
 
1.1 
(2.6%) 
0.88 
Lt Parotid 
mean 
 
51.9 ± 12.6 
 
53.6 ± 12.0 
 
1.7 
(3.3%) 
0.50 
Rt Parotid 
mean 
 
45.0 ± 13.1 
 
46.6 ± 14.3 
 
1.6 
(3.6%) 
0.80 
* One patient excluded due to incomplete voluming 
OAR - organ at risk 
SD - standard deviation 
GTV-p - primary gross target volume 
GTV-n - nodal gross target volume 
 
  
 
 
 
  
